Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Announces it has entered into a non-binding amended and restated Letter of Intent for a business combination with Braxia Scientific Corp., a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders. The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares of Braxia. Irwin Naturals Inc shares C.IWIN are trading up $0.20 at $3.95.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.
Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).